Lipids panel
Searched over 200M research papers for "lipids panel"
Summary
10 papers analyzed
These studies suggest that various advanced lipid panel methods, including NMR ELP assays, UPLC-MS/MS, LC-MS/MS, LipidSeq, and Lipidest, offer efficient, accurate, and cost-effective ways to measure and analyze lipids for clinical decision-making, diagnosis of lipid disorders, and identification of disease biomarkers.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta19 papers analyzed
Comprehensive Insights into Lipid Panel Assays and Their Clinical Applications
Introduction to Lipid Panel Assays
Lipid panel assays are essential diagnostic tools used to measure various lipids in the blood, including total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). These measurements are crucial for assessing cardiovascular disease risk and guiding therapeutic decisions.
Extended Lipid Panel (ELP) Using NMR Technology
Recent advancements have led to the development of the Extended Lipid Panel (ELP) assay, which utilizes nuclear magnetic resonance (NMR) technology. This method allows for the simultaneous measurement of TC, TG, HDL-C, and apolipoprotein B (apoB), providing a more comprehensive lipid profile. The ELP assay has shown excellent agreement with traditional chemical methods, demonstrating high precision and consistency across different testing sites. The inclusion of apoB in routine lipid panels could enhance clinical decision-making by providing a more accurate assessment of lipid-lowering therapy needs.
High-Throughput Lipid Profiling with LC-MS/MS
Lipidomics, the large-scale study of pathways and networks of cellular lipids, has been revolutionized by high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS). This approach enables the detailed quantification of a broad range of lipid species, facilitating the study of lipid metabolism in various clinical contexts. For instance, a comprehensive LC-MS/MS method has been developed to analyze 795 lipid species in human plasma, providing insights into metabolic health and disease states. This method is highly precise and can distinguish between different clinical and ethnic backgrounds, highlighting its potential for personalized medicine.
LipidSeq: Genetic Insights into Dyslipidemias
The LipidSeq panel is a targeted sequencing tool designed to identify genetic variants associated with dyslipidemias. By analyzing 69 genes and 185 single-nucleotide polymorphisms (SNPs), LipidSeq can detect both monogenic and polygenic forms of dyslipidemia. This panel has been instrumental in diagnosing and understanding the genetic basis of lipid disorders, leading to improved treatment options for patients . The high concordance with traditional sequencing methods and the ability to uncover novel disease mechanisms underscore its clinical utility.
Point-of-Care Lipid Testing with Lipidest
The Lipidest system represents a significant advancement in point-of-care lipid testing. This portable device integrates a spinning disc and an office scanner to perform a complete lipid panel from a finger-prick blood sample. The system eliminates the need for complex sample preparation and provides accurate results comparable to laboratory standards. Its simplicity and low cost make it ideal for use in resource-constrained settings, facilitating timely disease screening and management.
Lipid Biomarkers in Disease Diagnosis
Lipidomics has also been applied to identify biomarkers for various diseases. For example, specific lipid profiles have been associated with squamous cell carcinoma (SqCC), providing insights into the disease's biological behavior and potential diagnostic markers. Similarly, lipid biomarkers have been identified for chronic obstructive pulmonary disease (COPD), offering noninvasive methods for early detection and disease monitoring. In breast cancer, a lipid-based biomarker panel has shown promise in assessing risk, particularly among obese individuals, highlighting the role of metabolic health in cancer risk.
Conclusion
Advancements in lipid panel assays, from NMR-based ELP to high-throughput LC-MS/MS and genetic sequencing with LipidSeq, have significantly enhanced our ability to diagnose and manage lipid disorders. These technologies provide comprehensive lipid profiles, genetic insights, and point-of-care testing options, paving the way for personalized and precise medical interventions. Additionally, the identification of lipid biomarkers in various diseases underscores the critical role of lipidomics in modern clinical research and diagnostics.
Sources and full results
Most relevant research papers on this topic
